Oncology News | pharmaphorum

News

Trial data raises questions about Imfinzi in liver cancer

AstraZeneca is trying to blaze a new trial for immunotherapy in liver cancer with its EMERALD-1 trial, but the jury is out on its prospects.

News

BMS eyes first-line colorectal cancer use for Opdivo-Yervoy

The combination of Bristol-Myers Squibb’s Opdivo and Yervoy cancer immunotherapies is on track for approval as a first-line therapy for patients with a particular form of

News

CG Oncology lines up $180m IPO and a $1bn valuation

CG Oncology is the latest biotech to take a look at a share listing in the US, aiming to raise around $180 million in the process, in another sign of a possible recovery i

News

NICE backs Pfizer’s Talzenna for advanced breast cancer

Pfizer’s PARP inhibitor Talzenna has become the first targeted treatment for HER2-negative locally advanced or metastatic breast cancer with BRCA1/2 mutations to be recomm

News

BridgeBio raises $1.25bn, and other biotech financings

Our round-up of recent biotech financings is headed by a massive $1.25 billion round for genetic medicines specialist BridgeBio Pharma, with smaller rounds for Tr1X, Coman

News

FDA clears AI skin cancer detection device from DermaSensor

Medtech company DermaSensor has claimed FDA approval for a handheld device, powered by artificial intelligence (AI), that can be used to detect skin cancer at the point of

Trial data raises questions about Imfinzi in liver cancer

BMS eyes first-line colorectal cancer use for Opdivo-Yervoy

CG Oncology lines up $180m IPO and a $1bn valuation

NICE backs Pfizer’s Talzenna for advanced breast cancer

BridgeBio raises $1.25bn, and other biotech financings

FDA clears AI skin cancer detection device from DermaSensor

Amazon puts $100m into global health drive

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks